ClostraBio

Executive Summary

ClostraBio is a preclinical-stage biotechnology company pioneering next-generation probiotics and advanced metabolite delivery solutions for inflammatory bowel disease (IBD) and food allergies. Founded in 2019 and based in Chicago, the company leverages the gut microbiome to develop live biotherapeutic products (LBPs) that restore microbial balance and deliver therapeutic metabolites directly to the site of inflammation. Their platform addresses key limitations of conventional probiotics by engineering strains with enhanced stability, colonization, and production of anti-inflammatory molecules. With no disclosed funding or pipeline details, ClostraBio remains in early development, focusing on novel mechanisms to modulate the gut-immune axis. The potential of microbiome-based therapies in IBD and allergy is supported by growing clinical validation, but the company faces significant technical and regulatory hurdles. Its progress will depend on securing financing, advancing preclinical programs, and differentiating from competitors like Vedanta Biosciences and Seres Therapeutics. The current lack of publicly available data limits conviction, but the approach aligns with emerging trends in precision microbiome modulation.

Upcoming Catalysts (preview)

• Q3 2026Series A or Seed Extension Funding60% success
• Q4 2026IND-Enabling Studies Initiation for Lead Program40% success
• Q1 2027Presentation of Preclinical Proof-of-Concept Data at Major Conference50% success